Total-body contrast-enhanced MRA on a short, wide-bore 1.5-T system: intra-individual comparison of Gd-BOPTA and Gd-DOTA

Eur Radiol. 2008 Oct;18(10):2265-73. doi: 10.1007/s00330-008-0976-z. Epub 2008 Apr 23.


Total-body contrast-enhanced MRA (CE-MRA) provides information of the entire vascular system according to a one-stop-shop approach. Short, wide-bore scanners have not yet been used for total-body CE-MRA, probably due to their restricted field of view in the z-direction. The purpose of this feasibility study is to introduce an image protocol for total-body MRA on a short, wide-bore system. The protocol includes five to six table-moving steps and two injection runs. Two pharmacologically different contrast materials (CM) were applied in ten healthy volunteers in view of possible CM-dependent influences on the protocol outcome (Gd-Bopta, Gd-Dota). Differences consisted of significantly higher CNR with Gd-Bopta with a mean of 73.8+/-38.7 versus 69.1+/-34.3 (p=0.008), significantly better arterial visualization values with Gd-Dota with a mean of 1.26+/-0.44 versus 1.53+/-0.73 (p=0.003) and a tendency to less venous overlay with Gd-Dota, mean 1.19+/-0.44 and 1.34+/-0.72, respectively (p=0.065) (two-tailed Wilcoxon matched-pairs test). Overall 94% of the steps were valued as qualitatively excellent or good. The good results with both CM suggest a transfer to further patient evaluation.

Publication types

  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Arteries / anatomy & histology*
  • Contrast Media
  • Equipment Design
  • Equipment Failure Analysis
  • Feasibility Studies
  • Female
  • Heterocyclic Compounds*
  • Humans
  • Magnetic Resonance Angiography / instrumentation*
  • Magnetic Resonance Angiography / methods*
  • Male
  • Meglumine / analogs & derivatives*
  • Middle Aged
  • Organometallic Compounds*
  • Whole Body Imaging / methods*
  • Young Adult


  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • gadobenic acid
  • Meglumine
  • gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate